The GCIG Fall Meeting was held virtually in split sessions on November 18, November 21, and December 6, 2024. The meeting was shortened, and focused mainly on the concepts of pragmatic trials. Discussions emphasized the urgent need for practical, affordable, and practice-changing real-world clinical trials designed to produce results applicable to the general population rather than idealized patient cohorts. The value of real-world data, routinely collected from diverse sources outside traditional clinical research settings, was underscored.

Several ideas for pragmatic trials were introduced as well. Efforts should focus on collecting only essential patient data for analysis, reducing the volume of the data gathered, and on streamlining research processes. The key research questions include determining the optimal duration of CPi and PARPi treatment, exploring treatment sequencing, and evaluating strategies for treatment de-escalation. A persistent challenge remains that many novel therapeutics, while impactful in driving global practice changes, are unlikely to be accessible across all clinical settings and countries.

The GCIG's vision of ending gynecologic cancer through global, collaborative research must continue to guide these efforts.